Pharmacogenetics of Tacrolimus and Sirolimus in Renal Transplant Patients: From Retrospective Analyses to Prospective Studies

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2142-2144

  Anglicheau, D ^a   Legendre, C ^a   Thervet, E ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A; EVEROLIMUS; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG OVERDOSE; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS;

EID: 34548676182     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.018     Document Type: Article

References (10)

1. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487
2. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473
3. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383
4. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147
5. Hesselink D.A., van Schaik R.H., van der Heiden I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245
6. MacPhee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486
7. Thervet E., Anglicheau D., King B., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76 (2003) 1233
8. Anglicheau D., Verstuyft C., Laurent-Puig P., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14 (2003) 1889
9. Anglicheau D., Le Corre D., Lechaton S., et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 5 (2005) 595
10. Le Meur Y., Djebli N., Szelag J.C., et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80 (2006) 51